The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Subscribe To Our Newsletter & Stay Updated
